Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
Author: Elad, S.
Cheng, K.K.F.
Lalla, R.V.
Yarom, N.
Hong, C.
Logan, R.M.
Bowen, J.
Gibson, R.
Saunders, D.P.
Zadik, Y.
Ariyawardana, A.
Correa, M.E.
Ranna, V.
Bossi, P.
Arany, P.
Al-Azri, A.R.
Blijlevens, N.
Hovan, A.
Fregnani, E.
Fulton, J.
et al.
Citation: Cancer, 2020; 126(19):4423-4431
Publisher: Wiley
Issue Date: 2020
ISSN: 0008-543X
Statement of
Sharon Elad, Karis Kin Fong Cheng, ajesh V. Lalla, Noam Yarom, Catherine Hong, Richard M. Logan, Joanne Bowen, Rachel Gibson, Deborah P. Saunders, Yehuda Zadik, Anura Ariyawardana, Maria Elvira Correa, Vinisha Ranna, and Paolo Bossi, for the Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) include: Praveen Arany, Abdul Rahman Al-Azri ... Emma H. Bateman ... Janet K. Coller, Noor Al-Dasooqi, and Hannah Wardill. Other contributors include (in alphabetic order): Suzanne Ameringer ... Dorothy Keefe ... Bronwen Mayo ... Andrea M. Stringer ... et al.
Abstract: Mucositis is a significant toxicity of cancer therapy with numerous systemic sequelae. The goal of this systematic review was to update the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) Clinical Practice Guidelines for the management of mucositis. METHODS: The literature was reviewed systematically to identify interventions for mucositis. Studies were rated according to the presence of major and minor flaws according to previously published criteria. The body of evidence for each intervention and in each treatment setting was assigned a level of evidence based on previously published criteria. Guidelines were developed based on the level of evidence, with 3 possible guideline determinations: recommendation, suggestion, or no guideline possible. RESULTS: The guideline covers evidence from 1197 publications related to oral or gastrointestinal mucositis. Thirteen new guidelines were developed for or against the use of various interventions in specific treatment settings, and 11 previous guidelines were confirmed after aa review of new evidence. Thirteen previously established guidelines were carried over because there was no new evidence for these interventions. CONCLUSIONS: The updated MASCC/ISOO Clinical Practice Guidelines for mucositis provide professional health caregivers with a clinical setting-specific, evidence-based tool to help with the management of mucositis in patients who have cancer. Cancer 2020;126:4423-4431.
Keywords: cancer; gastrointestinal; guidelines; mucositis; Multinational Association of Supportive Care in Cancer and International Society for Oral Oncology (MASCC/ISOO); oral
Description: Published online July 28, 2020 in Wiley Online Library (
Rights: © 2020 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
DOI: 10.1002/cncr.33100
Published version:
Appears in Collections:Aurora harvest 8
Medicine publications

Files in This Item:
File Description SizeFormat 
hdl_128788.pdfPublished version180.27 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.